3[4]Collaborative Normal-Tension Glaucoma Study Group.Comparison of glaucomatous progressi on between un-treated patients with normaI-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol,1998,126:487～497
4[5]Bhandari A,Crabb DP,Poinoosawmy D,et al.Effect of surgery on visual field progression in normal-tension glaucoma.Ophthahnology,1997,104:1131～1137
7[8]Schulzer M. httraocular pressure reduction in normal-tension glaucoma patients.The Normal Tension Glaucoma Study Group.Ophthalmology,1992,99:1468～1470
8[9]Geijssen HC. Studies on Normal Pressure Glaucoma.Am-sterdam.Kugler Publishers,1991.161
9[10]Javitt J,Goldberg I.Comparison of the clinical success rates and quality of life effects of brimonidine tartrate 0.2%and betaxolol 0.25%suspension in patients With open-angle glaucoma and ocular hypertension.Brimonidine Outcomes Study Group II.J Glaucoma,2000,9:398～408
10[11]Nordlund JR,Pasquale LR,Robin AL,et al. The cardiovascular,pulmonary,and ocular hypotensive effects of 0.2% brimonidine.Arch Ophthalmol,1995,113:77～83
7[1]Quigley HA. Number of people with glaucoma worldwide[J]. BrJ Ophthalmol 1996;80;389 393.
8[2]Lkuo A, Hiroshi K. Hajime N,et al. Effects of mecobalamin on the visual field chronic glaucoma [J]. Folia Ophth J 1983;34(4):873-878.
9[3]Wilson R,Walker AM,Dueker DK,et al,Risk factors for rate of progression of glaucomatous visual field loss. a computer based analysis[J]. Arch Ophthalmol 1982; 100: 737 741.
10[4]Suzuki Y,Yokoama Y,Mizuno A,et al. Clinical use of mecobal amin [J]. Jap Rev Clin Ophthalmol 1981; 75 : 217-223.
6[7]Alsagoff Z,Aung T,Ang L P,et al.Long term clinical course of primary angle-closure glaucoma in an Asian population.Ophthalmology,2000,107(12):2300～2304
7[8]Rosman M,Aung T,Ang L P,et al,liebmann J M,Ritch R.Chronic angle-closure with glaucomatous damage:long term clinical course in a North American population and comparison with an Asian population.Ophthalmology,2002,109(12):2227～2231
